Senolytic
A senolytic (from the words “senescence” and “lytic” – destroying) is among a class of small molecules under basic research to determine if they can selectively induce death of senescent cells.[1] A goal of this research is to develop agents to delay, prevent, alleviate, or reverse age-related diseases.[2][3] A related concept is "senostatic", which means to suppress senescence.
Research
Multiple possible senolytic agents are under investigation.[4] In low doses, anti-cancer agents are one class of candidate compounds,[5][6] such as Navitoclax (also known as ABT-263).[7]
Senolytic candidates
 | This section needs more reliable medical references for verification or relies too heavily on primary sources. (July 2019) |  |
- Combination of Dasatinib and quercetin
- Fisetin
- Navitoclax
See also
References
- ^ Childs BG, Durik M, Baker DJ, van Deursen JM (2015). "Cellular senescence in aging and age-related disease: from mechanisms to therapy". Nature Medicine. 21 (12): 1424–35. doi:10.1038/nm.4000. PMC 4748967. PMID 26646499.
- ^ Kirkland JL, Tchkonia T (2015). "Clinical strategies and animal models for developing senolytic agents". Experimental Gerontology. 68: 19–25. doi:10.1016/j.exger.2014.10.012. PMC 4412760. PMID 25446976.
- ^ Jan M. van Deursen (2019). Senolytic therapies for healthy longevity. Science: 364(6441), 636-637 doi:10.1126/science.aaw1299
- ^ Baumann, Kim (2018-07-27). "Rejuvenating senolytics". Nature Reviews Molecular Cell Biology. 19 (9): 543. doi:10.1038/s41580-018-0047-5. ISSN 1471-0072. PMID 30054558.
- ^ Blagosklonny MV (2013). "Selective anti-cancer agents as anti-aging drugs". Cancer Biology & Therapy. 14 (12): 1092–7. doi:10.4161/cbt.27350. PMC 3912031. PMID 24345884.
- ^ Slack C, Alic N, Partridge L (2015). "Could cancer drugs provide ammunition against ageing?". Cell Cycle (Georgetown, Tex.). 15 (2): 153–5. doi:10.1080/15384101.2015.1118905. PMC 4825846. PMID 26587873.
- ^ Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW (2008). "Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models". Clinical Cancer Research. 14 (11): 3268–77. doi:10.1158/1078-0432.CCR-07-4622. PMID 18519752. Retrieved 2015-12-30.